Core Viewpoint - The announcement highlights a clinical collaboration between Kogei Pharmaceuticals and Dispatch Bio to initiate a Phase I clinical trial in China by 2026, focusing on the application of the combined therapy DISP-11 in patients with solid tumors [1] Group 1: Clinical Trial Details - The Phase I clinical trial will evaluate the combined therapy DISP-11, which includes Dispatch's investigational therapy developed on the Flare platform, featuring a novel tumor-specific virus DV-10 [1] - The combined therapy will also utilize Kogei Pharmaceuticals' targeted BCMA autologous CAR-T cell product, Zekai (CT053), which has already received approval from the National Medical Products Administration (NMPA) in China for the treatment of multiple myeloma [1]
科济药业：与Dispatch Bio达成临床合作，探索Flare平台与赛恺泽 在实体瘤中的应用